Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Thomas C. Indelicarto, Executive Vice President, General Counsel & Secretary at Verisign INC/CA (NASDAQ:VRSN), sold 501 shares of common stock on October 14, 2025, at a price of $262.92, for a total transaction value of $131,722.
Following the transaction, Indelicarto directly owns 34,189.2718 shares of Verisign. The company maintains a "GOOD" financial health score according to InvestingPro, which identifies 8 additional key investment factors for this stock, including management’s aggressive share buyback program.
In other recent news, VeriSign Inc. announced a significant development involving its board of directors and major shareholders. The company has appointed Matthew J. Desch, currently the CEO of Iridium Communications Inc., to its board, expanding the board size from seven to eight members. In another development, Berkshire Hathaway, a long-time stockholder of VeriSign, is set to reduce its stake in the company. Affiliates of Berkshire Hathaway will sell 4.3 million shares of VeriSign common stock at $285 per share through a secondary offering managed by J.P. Morgan Securities LLC. This transaction aims to decrease Berkshire Hathaway’s ownership below the 10% threshold, thereby avoiding additional regulatory requirements. VeriSign will not receive any proceeds from this sale, as all proceeds will go to the selling stockholders. These recent changes come as Berkshire Hathaway has been involved with VeriSign since 2012.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.